Table 1 Summary of clinical HIV remission trials in the RV254/SEARCH010 cohort in Bangkok, Thailand

RV 411

Fiebig I, on ART for ≥ 96 weeks, HIV RNA < 50 copies/mL for ≥ 48 weeks, integrated HIV DNA in PBMCs of < 10 copies/10⁶ PBMCs, and CD4 T cell of ≥ 400 cells/mm³

N/A (study of early ART only)

Up to 24 weeks

Viral rebound was observed in all participants and at a median time of 26 days. ART started in Fiebig I stage did not prevent or delay viral rebound

[59]

RV 397

Fiebig I–III, on ART for ≥ 96 weeks, HIV RNA < 50 copies/mL for ≥ 48 weeks, integrated HIV DNA in PBMCs of < 10 copies/10⁶ PBMCs, and CD4 T cell of ≥ 400 cells/mm³

VRC01 40 mg/kg IV every 3 weeks for up to 24 weeks

Up to 48 weeks

VRC01 was generally safe and was associated with a trend toward delayed viral rebound: the placebo group experienced viral rebound at a median of 14 days, whereas participants in the VRC01 group at a median of 26 days

[60]

RV 409

Fiebig III–IV, on ART for ≥ 42 weeks, HIV RNA < 50 copies/mL for ≥ 28 weeks, CD4 T cell of ≥ 450 cells/mm³

Vorinostat PO 400 mg/day 14 days on/off (3 cycles), hydroxychloroquine PO 200 mg BID, maraviroc PO 600 mg BID for 10 weeks

Up to 24 weeks

VHM was well tolerated in the majority of participants. No changes in total HIV DNA in PBMCs were described. All Fiebig III/IV treated participants had viral rebound after ATI; median time to viral rebound was 22 days

[61]

RV 405

Fiebig I–IV, on ART for ≥ 4 weeks, HIV RNA < 50 copies/mL for ≥ 48 weeks, CD4 T cell of ≥ 400 cells/mm³

Ad26 vaccine 5 * 10¹⁰ viral particle per 0.5 mL IM at week 0 and 12, MVA vaccine 10⁸ plaque-forming unit per 0.5 mL IM at week 24 and 48

Up to 36 weeks

Ad26/MVA was well-tolerated and it contributed to a modest delay in time to viral rebound after analytic treatment interruption

[62]